Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted monoclonal antibody therapeutics designed to treat Alzheimer's disease. The firm's research centers on identifying and neutralizing toxic soluble amyloid-beta oligomers (AβOs), which are recognized as early triggers and persistent drivers of synaptic dysfunction and neurodegeneration. Their lead drug candidate, sabirnetug, aims to halt or slow down the cognitive decline associated with early Alzheimer's disease.